Abstract
Breast cancer is a malignant tumor which has the highest incidence in the world, serious threatening to women's health. Surgery and chemotherapy are the general symmetric therapy for breast cancer. However, the worse prognosis is in triple-negative breast cancer (TNBC) compared with other types of breast cancer due to lack of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). The characteristics of low differentiation and high heterogeneity cause the tumor cells to metastasize more easily, resulting in less effect on traditional drug treatment. For now, immune checkpoint inhibitors (ICIs) show greater effect on treating some kinds of cancers by restoring T cells function. But the clinical results in TNBC are still not very satisfactory, some researchers suggest the combination treatment of ICIs with drug or target therapy can provide better effects. This review summarizes the results in clinical trials in both ICI and ICI-chemotherapy combination, describes the possibility explanations, and discuss the challenges and prospects of ICIs in the treatment of TNBC.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
